Cadila Healthcare has informed that it has enclosed a copy of press release dated December 4, 2020 titled ‘Zydus receives approval from DCGI to commence Phase III clinical trials with Pegylated Interferon alpha-2b in India’. The contents of the press release give full details. Bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.
The above information is a part of company’s filings submitted to BSE.